Skip to main content
Figure 2 | Journal of Neuroinflammation

Figure 2

From: Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis

Figure 2

Interleukin 1β does not influence disease inflammatory activity in relapsing–remitting multiple sclerosis. (A) and (B) Survival analyses for the time to first clinical relapse (A) and the time to detecting an active magnetic resonance imaging (MRI) scan since diagnosis (B), among participants with detectable or undetectable levels of interleukin 1β (IL-1β) in the cerebrospinal fluid. No significant differences were observed.

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094